Larotrectinib sulfate

硫酸拉罗替尼

Report date: 2026/05/26 20:00:28
NMEFirst In Class

Base Information

Drug NameLarotrectinib sulfate
Drug Alias Name拉洛替尼LarotrectinibLarotrectinibumVitrakvi维泰凯 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNerve growth factor receptor Trk-A antagonistsNeurotrophic tyrosine kinase receptor type 2 inhibitorsNeurotrophic tyrosine kinase receptor type 3 inhibitors +[4] 
TargetsNeurotrophic tyrosine kinase receptor type 3Nerve growth factor receptor Trk-ANeurotrophic tyrosine kinase receptor type 2 +[4] 
Therapy Area/IndicationsSolid tumoursXanthogranuloma, JuvenileHistiocytosis, Langerhans-Cell +[48] 
Global Approved IndicationsSolid tumoursNeoplasms
Approved Indications in ChinaSolid tumours
Original Approved Country/TerritoryUnited States
Original Approved Date2018/11/26
Country/TerritoryCzechiaBelgiumCanada +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesArray Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesPci (Penn Pharmaceutical Services Ltd) TredegarBayer HealthcareNational Cancer Institute +[6] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsSolid tumoursXanthogranuloma, JuvenileHistiocytosis, Langerhans-Cell +[47] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01EX12
Related LinksWikipediaDrugBankKEGG